Autolus Therapeutics (AUTL) Interest Expenses (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Interest Expenses came in at $22.8 million in Q4 2025, up 174.06% YoY from $8.3 million in Q4 2024, and down 80.76% on a QoQ basis from $118.7 million in Q3 2025.
Autolus Therapeutics (AUTL) Interest Expenses (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Interest Expenses data on file, last reported at $22.8 million in Q4 2025.
- Quarterly Interest Expenses rose 174.06% year-over-year to $22.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.9 million (up 38.38% YoY) and the FY2025 annual result came in at $248.0 million, up 57.98% from the prior year.
- Interest Expenses eased to $22.8 million in Q4 2025, from $118.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $119.8 million in Q2 2025 to a low of -$30.8 million in Q4 2024.
- A 5-year average of $24.3 million and a median of $5.0 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 4769.01% — and 2024, when it plunged 202.35%.
- Tracing AUTL's Interest Expenses over 5 years: stood at $71000.0 in 2021, then jumped by 4769.01% to $3.5 million in 2022, then jumped by 771.51% to $30.1 million in 2023, then sank by 202.35% to -$30.8 million in 2024, then jumped by 174.06% to $22.8 million in 2025.
- The last three Interest Expenses figures came in at $22.8 million (Q4 2025), $118.7 million (Q3 2025), and $119.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 144.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.54 Mn |
| Jun 30, 2026 | 144.54 Mn |
| Dec 31, 2025 | 22.84 Mn |
| Dec 31, 2025 | 22.84 Mn |
| Sep 30, 2025 | 118.71 Mn |
| Sep 30, 2025 | 118.71 Mn |
| Jun 30, 2025 | 119.82 Mn |
| Jun 30, 2025 | 119.82 Mn |
| Mar 31, 2025 | 110.97 Mn |
| Mar 31, 2025 | 110.97 Mn |
| Dec 31, 2024 | -30.84 Mn |
| Dec 31, 2024 | -30.84 Mn |
| Sep 30, 2024 | 10.69 Mn |
| Sep 30, 2024 | 10.69 Mn |
| Jun 30, 2024 | 10.17 Mn |
| Jun 30, 2024 | 10.17 Mn |
| Mar 31, 2024 | 19.27 Mn |
| Mar 31, 2024 | 19.27 Mn |
| Dec 31, 2023 | 30.13 Mn |
| Dec 31, 2023 | 30.13 Mn |